All In Biotech

Drug Trial Radar · NCT03454646

Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)

Comparison of Therapeutic Strategies With Cholinesterase Inhibitors: Stop or Still (SOS) Trial

Last checked: Nov 19, 2026Latest source record: Oct 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 1,205 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,205

Planned (sponsor's estimate)

Start

Jun 1, 2024

Primary completion

Apr 27, 2027

Study completion Sep 15, 2027

Sponsor

Lead sponsor
University Hospital, BordeauxAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 6, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cholinesterase inhibitors (CI) remain the only drugs with a recognized efficacy in mild to moderate Alzheimer's disease (AD) in spite of enormous research efforts. However, these drugs presented as "symptomatic treatment" of AD are considered as having only a weak effect on the course of AD. The reimbursement of these drugs is regularly challenged due to the lack of evidence for the impact of these drugs on milestones stages of AD evolution (survival without severe dementia, restriction in Basic Activities of Daily Living - BADL) and on major consequences in public health (hospitalization and institutionalization). The great majority of previous randomized controlled trials conducted with CI have had a too short duration and the end points were limited to cognition (ADAS Cog scale), IADL (Instrumental Activities of Daily Living) function and Global Impression of Change. New evidences from the DOMINO trial (1) conducted in UK, independently of the pharmaceutical industry, showed that the true effect of CI might be more to avoid or to delay the cognitive or functional decline in AD than to improve patients; the institutionalisation (2) was also delayed. However, this trial was conducted in patients with moderate to severe AD, and the interest of the drugs at the mild to moderate stage remains questionable. The investigators have shown that a good surrogate marker of survival without severe dementia would be an increase of ADAS Cog scale of more than six points (3). A post hoc reanalysis of the pivotal RCT with two CI showed that in mild to moderate patients, CI was associated with a 15% decrease of patients with a deterioration of ADAS-Cog of more than six points in six months. Thus at the beginning of dementia the real effect of CI might be more of delaying the cognitive and functional decline, than to improve the patients. The main objective of the SOS trial is to demonstrate that the benefit of CI at the early phase of dementia is the same as at the later phase.

Conditions

  • Alzheimer Disease
  • Cholinesterase Inhibitors

Interventions

  • cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine)Drug

    The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual. All the recruited patients will be treated by CI according to the recommendations of the French HAS and the clinician's habits to choose the type of CI and adjust the dosage. After a 6-month period under CI treatment, patients will be classified according to the evolution of the Mini Mental State Examination (MMSE) as "non-responders" or responders. Responders patients will continue their treatment according to the habits of the clinician. Non-responder patients will be included in the RCT, with individual randomization in two groups: one group who stops the CI, one group who continues the CI. All randomized patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary outcome is a combination of complete BADL dependency in bathing and dressing and/or institutionalization or death at 2 years after randomization.Time frame: at 30 months after patient's inclusion

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • CHU d'Amiens Centre Mémoire Ressources Recherche

    Amiens, France

  • CHU d'Angers Centre Mémoire Ressources Recherche

    Angers, France

  • CHU de Bastia Centre Mémoire Ressources Recherche

    Bastia, France

  • CHU de Besançon Centre Mémoire Ressources Recherche

    Besançon, France

  • CHU de Bordeaux - Service de Neurologie - Centre Mémoire Ressources Recherche -

    Bordeaux, France

  • CHRU Cavale Blanche Service de Gériatrie

    Brest, France

  • Service de Neuropsychologie Hôpital Neurologique Pierre Wertheimer

    Bron, France

  • CHU Côte de Nacre Service de neurologie et CMRR

    Caen, France

  • CHU de Clermont Ferrand Centre Mémoire Ressources Recherche

    Clermont-Ferrand, France

  • Hôpital Pasteur Service de Neurologie

    Colmar, France

  • CHU de Dijon- CMRR

    Dijon, France

  • Chu de Grenoble CMRR, Neurologie

    Grenoble, France

  • Hôpital Roger Salengro CMRR

    Lille, France

  • CHU Limoges Service de neurologie et CMRR

    Limoges, France

  • AP-HM

    Marseille, France

  • CHU Montpellier Hôpital Gui de Chauliac CMRR

    Montpellier, France

  • CHU de Nantes Clinique Neurologique Hôpital GR Laennec

    Nantes, France

  • Institut Claude Pompidou Centre Mémoire de Ressources et de Recherche

    Nice, France

  • APHP Hôpital Broca

    Paris, France

  • Hôpital Universitaire de la Pitié Salpêtrière Pavillon François Lhermitte

    Paris, France

  • APHP Groupe Hospitalier Saint Louis Lariboisière Fernand Widal CMRR

    Paris, France

  • CHU La Milétrie Pôle de Gériatrie

    Poitiers, France

  • CHU Reims Hôpital Maison Blanche Court Séjour Gériatrique

    Reims, France

  • CHU de Rennes - Hôpital Pontchaillou / Service de Neurologie

    Rennes, France

  • CHU de Rouen Hôpital Charles Nicolle Service Neurologie

    Rouen, France

  • Chu de Saint-Etienne, CMRR

    Saint-Etienne, France

  • Chu de Strasbourg Hôpital Ka Robertsau Pôle de Gériatrie - CMRR

    Strasbourg, France

  • Centre de Recherche Clinique du Gérontopôle Cité de la Santé

    Toulouse, France

  • CHRU de Bretonneau Unité de gérontopsychiatrie

    Tours, France

  • CHU Nancy Service de Gériatrie-CMRR

    Vandœuvre-lès-Nancy, France

  • Hospice Civil de Lyon Hôpital des Charpennes

    Villeurbanne, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.